Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity (2010 - 2026)

Abeona Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $198.5 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 99.76% year-over-year to $198.5 million in Q1 2026; TTM through Mar 2026 was $895.4 million, a 93.44% increase from a year earlier, with the FY2025 full-year figure at $219.6 million, up 101.57% from the prior year.
• Liabilities and Shareholders Equity retreated to $198.5 million in Q1 2026 per ABEO's latest filing, from $219.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $246.2 million in Q2 2025 and bottomed at $38.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $74.8 million (2024), against an average of $110.2 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 67.43% in 2022 and jumped 150.24% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $64.2 million in 2022, then fell by 0.33% to $64.0 million in 2023, then soared by 70.2% to $108.9 million in 2024, then soared by 101.57% to $219.6 million in 2025, then slipped by 9.6% to $198.5 million in 2026.
• Per Business Quant, the three latest ABEO Liabilities and Shareholders Equity figures stand at $198.5 million (Q1 2026), $219.6 million (Q4 2025), and $231.1 million (Q3 2025).